Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03336918
Other study ID # 17-441
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 7, 2017
Est. completion date December 1, 2025

Study information

Verified date April 2024
Source Brigham and Women's Hospital
Contact Lauren A Patton
Phone 216-636-1675
Email pattonl3@ccf.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Lithium is highly effective in the treatment of bipolar disorder. This study aims to investigate, for the first time, the impact of lithium monotherapy on the structural and functional connectivity of the brain using MRI imaging.


Description:

The premise of this proposal is that the clinical efficacy of lithium in bipolar disorder, and its complex effects on multiple brain physiological functions, may be best deciphered using a network properties-metric approach. This approach is critical because it provides insight into the function of brain networks (e.g., resilience to disruption, central hubs), which is likely to be more closely linked to behavioral outcomes. Furthermore, we will conduct an exploratory investigation of the in vivo molecular effects of lithium by measuring peripheral gene expression. To bring these together, we will also explore whether connectome changes serve as mediator between molecular changes (i.e., gene expression) induced by lithium treatment and behavioral changes (e.g., depression, mood stability, suicidality).


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date December 1, 2025
Est. primary completion date August 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion criteria for BD subjects: - ages 18-60 years (inclusive) and able to give voluntary informed consent; - Satisfy criteria for Diagnostic and Statistical Manual 5th edition (DSM-V) for BD I or II, current Depressive Episode; - 17-item Hamilton Depression Rating Scale (HAM-D) score >15 and <25; - Young Mania Rating Scale (YMRS) < 8; - no psychotropics in the last 2 weeks (if previously on fluoxetine then medication free for 5 weeks) OR on stable psychotropic medications for 12 weeks - no lithium treatment for past 6 months; - satisfy criteria to undergo an MRI scan based on MRI screening questionnaire; - able to be managed as outpatients during the study as ascertained by Clinical Global Severity Scale < 5 (i.e., moderately ill) and no significant suicidal or homicidal ideation or gross disability. Exclusion criteria for BD subjects are: - meeting DSM-IV criteria for schizophrenia, schizoaffective disorder, or an anxiety disorder as - a primary diagnosis; - requiring inpatient treatment; - meeting DSM-V criteria for substance dependence within the past 3 months, except caffeine or nicotine; - positive urinary toxicology screening at screening visit; - use of alcohol in the past 1 week; - serious medical or neurological illness; - current pregnancy or breast feeding; - metallic implants or other contraindications to MRI. Inclusion criteria for healthy subjects: - ages 18-60 years and ability to give voluntary informed consent; - no history of psychiatric illness or substance abuse or dependence; - no significant family history of psychiatric or neurological illness in first degree relative; - not currently taking any prescription or centrally acting medications; - no use of alcohol in the past 1 week; - and no serious medical or neurological illness. Exclusion criteria for healthy subjects are: - under 18 years of age; - pregnant or breast-feeding; - metallic implants or other contraindication to MRI.

Study Design


Intervention

Drug:
Lithium
Open-label lithium treatment for Bipolar Disorder Subjects Healthy Controls only repeat testing - no intervention

Locations

Country Name City State
United States Cleveland Clinic Foundation Center for Behavioral Health Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
Brigham and Women's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Functional Connectivity (Fc) changes Investigate effects of lithium monotherapy treatment of BD on changes in Fc through fMRI imaging from baseline after 2, 8, and 26 weeks of treatment and test whether these changes correlate with improvement in state-related symptoms and longer term mood stability. Healthy controls will also be scanned at the same time points but not treated. 2, 8, 26 weeks
Primary Structural Connectivity (Sc) changes Investigate effects of lithium monotherapy treatment of BD depression on changes in the diffusion weighted imaging Sc through fMRI imaging from baseline after 2, 8, and 26 weeks and test whether these changes correlate with depression severity and mood stability. Healthy controls will also be scanned at the same time points but not treated. 2, 8, 26 weeks
Secondary Changes in peripheral gene expression An exploratory investigation of whether lithium-related changes in the functional and structural connectome over time represent a link between shifts in peripheral gene expression and improvement in illness-related measures.Lithium therapy will be associated with changes in gene expression pathways such as the mitochondrial-carnitine shuttle pathway, which in turn will be related to changes in the functional and structural connectome. 2, 8, 26 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A